Sugi Predict

Sugi Predict / Compounds / SCHEMBL40190

SCHEMBL40190

SCHEMBL40190

CN(CC=O)C(=O)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.51
▸ SIGMAR1 Q99720 1/20 0.50
▸ MAPT P10636 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ HCAR2 Q8TDS4 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ SLC6A2 P23975 1/20 0.46
▸ SLC6A3 Q01959 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ CCR6 P51684 1/20 0.46
▸ PAX8 Q06710 1/20 0.46
▸ F13A1 P00488 1/20 0.45
▸ TGM2 P21980 1/20 0.45
▸ TGM1 P22735 1/20 0.45
▸ ABCB1 P08183 1/20 0.44
▸ LMNA P02545 2/20 0.44
▸ CHRNB2 P17787 1/20 0.43
▸ CHRNB4 P30926 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8370085 0.89 ALDH1A1 (0.53) ALDH1A1SIGMAR1MAPTHPGDHCAR2
SCHEMBL27508925 0.87 ALDH1A1 (0.51) ALDH1A1SIGMAR1MAPTHPGDHCAR2
SCHEMBL13684203 0.86 ALDH1A1 (0.50) ALDH1A1SIGMAR1MAPTHPGDHCAR2
SCHEMBL5540531 0.84 F13A1 (0.51) ALDH1A1SIGMAR1MAPTHPGDHCAR2
SCHEMBL70301 0.83 CCR6 (0.55) ALDH1A1SIGMAR1MAPTHPGDHCAR2
SCHEMBL7367495 0.83 ALDH1A1 (0.58) ALDH1A1SIGMAR1MAPTHPGDHCAR2
SCHEMBL19346033 0.82 CCR6 (0.48) ALDH1A1SIGMAR1MAPTHPGDHCAR2
SCHEMBL10107202 0.81 ALDH1A1 (0.56) ALDH1A1SIGMAR1MAPTHPGDHCAR2
SCHEMBL13687204 0.81 CHRNB2 (0.61) ALDH1A1MAPTHPGDMAPK1L3MBTL1
SCHEMBL27092718 0.81 CCR6 (0.50) ALDH1A1SIGMAR1MAPTHPGDHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570648-B2 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer LES LABORATOIRES SERVIER (FR) 2026-03-10 — — US disclosed
US-20250136550-A1 PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME THERAVANCE BIOPHARMA R&D IP, LLC 2025-05-01 — — US disclosed
US-20250034200-A1 Prodrugs of Neurosteroid Analogs and Uses Thereof UNIV EMORY (US) 2025-01-30 — — US disclosed
US-12054461-B2 Sulfonylurea derivatives and uses thereof NodThera Limited (GB) 2024-08-06 — — US disclosed
CN-118401497-A Crystalline acetone solvate of Lei Fen nacin 医药化学公司 2024-07-26 — — CN disclosed
EP-3468953-B1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE IP DEV LTD (GB) 2024-05-22 — — EP disclosed
CN-114450284-B 6, 7-Dihydro-5H-pyrido [2,3-C ] pyridazine derivatives as BCL-XL protein inhibitors 法国施维雅药厂 2024-05-07 — — CN disclosed
EP-3983387-B1 SULFONYLUREA DERIVATIVES AND USES THEREOF NODTHERA LTD (GB) 2024-04-24 — — EP disclosed
EP-4003989-B1 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER SERVIER LAB (FR) 2023-12-27 — — EP disclosed
CN-117263850-A Synthesis method of raffinacine 华中药业股份有限公司 2023-12-22 — — CN disclosed
CN-1232399-A Cysteine protease inhibitors SMITHKLINE BEECHAM CORP (US) 1999-10-20 — — CN disclosed
EP-0936912-A4 INHIBITORS OF CYSTEINE PROTEASE SMITHKLINE BEECHAM CORP (US) 1999-10-13 — — EP disclosed
EP-0936912-A1 INHIBITORS OF CYSTEINE PROTEASE SMITHKLINE BEECHAM CORPORATION (US) 1999-08-25 — — EP disclosed
US-5753652-A Antiretroviral hydrazine derivatives NOVARTIS CORPORATION (US) 1998-05-19 — — US disclosed
WO-1998005336-A1 INHIBITORS OF CYSTEINE PROTEASE SMITHKLINE BEECHAM CORPORATION (US) 1998-02-12 — — WO disclosed
EP-0465581-B1 ERYTHROMYCIN DERIVATIVES ABBOTT LAB (US) 1995-10-04 — — EP disclosed
US-5288709-A Erythromycin derivatives ABBOTT LABORATORIES (US) 1994-02-22 — — US disclosed
EP-0465581-A4 ERYTHROMYCIN DERIVATIVES — 1992-05-13 — — EP disclosed
EP-0465581-A1 ERYTHROMYCIN DERIVATIVES. ABBOTT LAB (US) 1992-01-15 — — EP disclosed
WO-1990011288-A1 ERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1990-10-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136550-A1 PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME CYP4B1, KDM4B, CYP3A4 ALDH1A1 648/4885SIGMAR1 3153/4885MAPT 3100/4885
US-12054461-B2 Sulfonylurea derivatives and uses thereof IL1B, NOD1, IL1A ALDH1A1 188/4885SIGMAR1 1057/4885MAPT 4413/4885
US-20250034200-A1 Prodrugs of Neurosteroid Analogs and Uses Thereof CYP11B2, CYP11B1, CYP21A2 ALDH1A1 645/4885SIGMAR1 2792/4885MAPT 1546/4885
US-12570648-B2 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer BCOR, BCL2A1, BAK1 ALDH1A1 2522/4885SIGMAR1 301/4885MAPT 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.